Table 2.

Logistic regression analysis of association between baseline factors and clinical and radiographic outcomes at Week 104 in patients randomized to CZP + MTX (n = 159) or PBO + MTX (n = 157)

	SDAI remission odds ratio (95% CI) P value		cRRP odds ratio (95% CI) P value
	Univariate	Multiple	Univariate	Multiple
Age	0.99 (0.97‐1.01) .322		1.00 (0.96‐1.04) .950
Gender	0.51 (0.29‐0.91) .022	0.51 (0.28‐0.92) .026	1.20 (0.44‐3.26) .727
BMI	0.94 (0.88‐1.01) .082	0.93 (0.87‐1.00) .051	0.97 (0.87‐1.08) .589
DAS28‐ESR	0.63 (0.51‐0.79) <.001	0.70 (0.53‐0.92) .012	2.03 (1.42‐2.90) <.001	1.63 (1.01‐2.62) .044
HAQ‐DI	0.56 (0.38‐0.80) .002	0.78 (0.48‐1.26) .309	2.32 (1.34‐4.02) .003	1.37 (0.67‐2.81) .393
mTSS	0.77 (0.61‐0.98) .032	0.80 (0.62‐1.02) .077	2.08 (1.50‐2.89) <.001	2.00 (1.37‐2.92) <.001
RF	1.00 (1.00‐1.00) .971		1.00 (1.00‐1.00) .009	1.00 (1.00‐1.00) .353
Anti‐CCP antibody	1.00 (1.00‐1.00) .381		1.00 (1.00‐1.01) .379
MMP‐3	1.00 (1.00‐1.00) .312		1.00 (1.00‐1.00) .024	1.00 (1.00‐1.00) .948
CZP treatment	1.71 (1.07‐2.73) .024	1.65 (1.01‐2.69) .047	0.33 (0.14‐0.76) .009	0.33 (0.13‐0.81) .017

Abbreviations: BMI, body mass index; CCP, cyclic citrullinated peptide; cRRP, clinically relevant radiographic progression; CZP, certolizumab pegol; DAS28‐ESR, Disease Activity Score of 28 joints ‐ erythrocyte sedimentation rate; HAQ‐DI, Health Assessment Questionnaire Disability Index; MMP‐3, matrix metalloproteinase; mTSS, van der Heijde modified total Sharp score; MTX, methotrexate; PBO, placebo; RF, rheumatoid factor; SDAI, simple disease activity index.

Bold indicates factors shown to reach significance in univariate/multivariate analyses.